Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody [0.03%]
利用PRL3在儿童实体瘤中频繁且特异的表达进行PRL3单克隆抗体(first-in-child)临床试验的研究
Amos Hong Pheng Loh,Min Thura,Abhishek Gupta et al.
Amos Hong Pheng Loh et al.
Phosphatase of regenerating liver 3 (PRL3) is a specific tumor antigen overexpressed in a broad range of adult cancer types. However, its physiological expression in pediatric embryonal and mesenchymal tumors and its association with clinic...
Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma [0.03%]
内源性H3.3K27M衍生肽特异性结合HLA-A*02：01，不足以针对弥漫内皮中间胶质瘤进行免疫治疗
Stacie S Wang,Kirti Pandey,Katherine A Watson et al.
Stacie S Wang et al.
Diffuse midline glioma (DMG) is a childhood brain tumor with an extremely poor prognosis. Chimeric antigen receptor (CAR) T cell therapy has recently demonstrated some success in DMG, but there may a need to target multiple tumor-specific t...
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives [0.03%]
胃肠疾病基因治疗的潜在疗效：进展与未来展望
Ning-Ning Yue,Hao-Ming Xu,Jing Xu et al.
Ning-Ning Yue et al.
Advancements in understanding the pathogenesis mechanisms underlying gastrointestinal diseases, encompassing inflammatory bowel disease, gastrointestinal cancer, and gastroesophageal reflux disease, have led to the identification of numerou...
Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL [0.03%]
低氧调控的IL-12分泌增强CD19 CAR-T细胞治疗DLBCL的抗肿瘤活性和安全性
Wenping Zhou,Jinxin Miao,Zhenguo Cheng et al.
Wenping Zhou et al.
CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy has been demonstrated as one of the most promising therapeutic strategies for treating B cell malignancies. However, it has shown limited treatment efficacy for di...
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions [0.03%]
一种双顺反子抗CD19/CD20嵌合抗原受体结构的构建及消除意外核酸序列缺失的方法开发
Norris Lam,Richard Finney,Shicheng Yang et al.
Norris Lam et al.
To address CD19 loss from lymphoma after anti-CD19 chimeric antigen receptor (CAR) T cell therapy, we designed a bicistronic construct encoding an anti-CD19 CAR and an anti-CD20 CAR. We detected deletions from the expected bicistronic const...
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy [0.03%]
具有嵌合VSV-NDV的溶瘤病毒疗法可协同支持RIG-I依赖性检查点抑制剂免疫疗法
Janina Marek,Lorenz Hanesch,Teresa Krabbe et al.
Janina Marek et al.
Unraveling the complexities of the tumor microenvironment (TME) and its correlation with responsiveness to immunotherapy has become a main focus in overcoming resistance to such treatments. Targeting tumor-intrinsic retinoic acid-inducible ...
Erratum: Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells [0.03%]
Correction：带有安全装置的抗CD117嵌合抗原受体T细胞能够消灭急性髓系白血病和造血干细胞
Chiara F Magnani,Renier Myburgh,Silvan Brunn et al.
Chiara F Magnani et al.
[This corrects the article DOI: 10.1016/j.omto.2023.07.003.]. © 2023 The Author(s).
Published Erratum
Molecular therapy oncolytics. 2023 Aug 20:30:150. DOI:10.1016/j.omto.2023.08.002 2023
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors [0.03%]
瘤内注射溶瘤痘苗病毒TG6002联合口服5-氟胞苷治疗恶性肿瘤犬的临床试验
Jérémy Béguin,Eve Laloy,Sandrine Cochin et al.
Jérémy Béguin et al.
TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modif...
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment [0.03%]
基于纳米抗体的双特异性CAR-T细胞疗法增强T细胞淋巴瘤治疗的抗肿瘤疗效
Baijin Xia,Keming Lin,Xuemei Wang et al.
Baijin Xia et al.
T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate. The current therapeutic regimens have relatively low efficacy rates. Clinical studies of single-target chimeric an...